维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

14篇 您的检索式：作者名="Ltibbert M"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	CD34^- hematopoietic stem cells : current concepts and controversies 显示文摘	Guo Y Ltibbert M Engelhardt M	2003	Stem Cells2003，21，1：	1
	2	Histone deacetylase(HDAC) inhibitors in recent clinical trials for cancer therapy 显示文摘	Wagner JM Hackanson B Ltibbert M	2010	Clin Epigenetics2010，1，34：	1
	3	Low-dose decitabine ver- sus best supportive care in elderly patients with intermediate or high-risk myelodysplastic syndrome (MDS) ineligible for in- tensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treat- ment of Cancer Leukemia Group and the German MDS Study Group显示文摘	Ltibbert M Suciu S Baila L	2011	J Clin Oncol2011，29，15：	1
	4	An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza- 2'-deoxycytidine (decitabine) in 177 patients 显示文摘	Wijermans PW Ltibbert M Verhoef G	2005	Ann I-Iemato12005，84，1：	1
	5	Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy:final results of the randomized phase m study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group 显示文摘	Ltibbert M Suciu S Baila L	2011	J Clin Oneo12011，29，15：	1
	6	Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent,for the treatment of high-risk myelodyspl- astie syndrome显示文摘	Wijermans P1 Ltibbert M	2000	J Clin Oncol2000，18，5：	1
	7	Epigenetic targets in hematopoi- etic malignancies 显示文摘	Claus R Ltibbert M	2003	Oncogene2003，22，42：	1
	8	Low-dose decitabine versus best supportive care in elderly patients with Inter- mediate-or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase 11 study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group显示文摘	Ltibbert M Suciu S Baila L	2011	J Clin Oncol2011，29，15：	1
	9	CXCR4 is a prognostic marker in acute myelogenous leukemia 显示文摘	Spoo AC Ltibbert M Wierda WG	2007	Blood2007，109，2：	1
	10	Clinical results with the DNA hypomethylating agent 5- aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes : an update 显示文摘	Joeckel TE Ltibbert M	2012	Semin Hematol2012，49，4：	1
	11	Low - dose decitabine versus-best supportive care in elderly patients with intermediate - or high risk myelodysplastie syndrome (MDS)ineligible for intensive chemotherapy: Final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group 显示文摘	Ltibbert M Suciu S Baila L	2011	J Clin Onco12011，29，15：	1
	12	A multicenter phase 1 trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy 显示文摘	Ltibbert M Rtiter BH Claus R	2012	Haematologica2012，97，3：	1
	13	A multieenter phase Ⅱ trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy 显示文摘	Ltibbert M Rtiter BH Claus R	2012	Hematologica2012，97，3：	1
	14	Low-dose 5- aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a muhicenter phase Ⅱ study in elderly patients 显示文摘	Wijermans P Ltibbert M Verhoef G	2000	J Clin Oncol2000，18，：	1

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费